Merck expands pact on Strep therapy

Merck is expanding its alliance with Intercell to find a new therapy for Group A Streptococcus. Their new pact includes a $9.5 million up front payment and up to $76 million in milestone payments. The agreement centers on antigens discovered using Intercell's technology platform. Merck gains development options on antibodies that can be directed against the antigens. Strep is a big driver of doctor's visits and a leading reason why doctor's prescribe antibiotics for children.

- read the AFX report on the pact

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.